Real-world Outcomes with Luspatercept

A recent real‑world U.S. cohort study examined first‑line Luspatercept in patients with lower‑risk Myelodysplastic Syndromes (LR‑MDS). The data show that using luspatercept up front—rather than delaying until after other therapies—leads to meaningful improvements in anemia and reduced transfusion dependence, closely mirroring results from controlled trials. Importantly, benefits extended across subgroups including patients without ring sideroblasts and those with lower baseline serum erythropoietin, indicating broad applicability. These findings strengthen the rationale for first-line luspatercept in routine clinical practice for LR‑MDS, offering a well‑tolerated and effective alternative to traditional erythropoiesis‑stimulating agents.